BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Regulatory actions for Nov. 12, 2020

Nov. 12, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bioelectronics, Perkinelmer, Spiderwort, Wren Laboratories.
Read More

Other news to note for Nov. 12, 2020

Nov. 12, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Applied DNA Sciences, Avicenna.AI, Becton Dickinson, Canon Medical Systems, Cb Scientific, Cubex, Decision Diagnostics, Djo, Fedoc, Isohelix, Mindray North America, Perspectum, Precision Genetics, Stryker, Tidepool, Virusight Diagnostic, Vizient, Zoll Medical.
Read More

Mymd heads to Nasdaq via reverse merger with Akers Biosciences

Nov. 12, 2020
By Michael Fitzhugh
Mymd Pharmaceuticals Inc., the privately held developer of a synthetic derivative of tobacco alkaloids for the potential treatment of autoimmune diseases and age-related disorders, will soon list on Nasdaq via its acquisition of former point-of-care testing company Akers Biosciences Inc., shares of which (NASDAQ:AKER) climbed 29.1% to $2.22 on Nov. 12. The combined company, to be headquartered in Baltimore, will retain Mymd's name and adopt the trading symbol MYMD. Concurrent with the merger, Akers is raising $18 million in a private placement priced at-the-market.
Read More
Data privacy illustration
Sharing without oversharing

Quick-ish cleanup can preserve privacy in functional genomics datasets

Nov. 12, 2020
By Anette Breindl
Researchers at Yale University have described what they have called a “data sanitization tool,” enabling them to strip personal identifiers out of functional genomics data while preserving their usefulness for research.
Read More
Vaccine administration

Anvisa restarts trials for Sinovac’s COVID-19 vaccine

Nov. 12, 2020
By Sergio Held and Alfred Romann
BOGOTA, Colombia and VANCOUVER, Canada – Anvisa, Brazil’s health care surveillance agency, re-started phase III trials for Coronavac, the COVID-19 vaccine candidate developed by China-based Sinovac Biotech Ltd., after a suspension of just two days. “Anvisa understands that it has sufficient subsidies to allow the resumption of vaccination,” the regulator said on Nov. 11. Anvisa said it plans to continue monitoring “the possible relationship of causality” between an unexpected serious adverse event and the vaccine.
Read More
Regulatory front

NICE news for patients with CLL, TTP

Nov. 12, 2020
By Mari Serebrov
The latest global regulatory news, changes and updates affecting biopharma, including: WHO maps end of the road for some tropical diseases; MHRA updates import licensing guidance.
Read More

Regulatory actions for Nov. 12, 2020

Nov. 12, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alzecure, Apollomics, Bavarian Nordic, Halozyme, Janssen, Mycovia, Neonmind, Valeo, Vasomune.
Read More

Other news to note for Nov. 12, 2020

Nov. 12, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aligos, Amcure, Annovis, Astrazeneca, Atara, BMS, CCT, Cherry, Curevac, Esperion, Greenwich, Handl, Hinova, ICER, Incyte, Jubilant, Kiadis, Morphosys, Nanobiotix, Novartis, Noxopharm, Onethree, Pluristyx, Sareum, Selva, Sierra, Triplet, Tufts, UCB, Vaxart, Vistagen, Wuxi, Xencor, Xilio.
Read More

In the clinic for Nov. 12, 2020

Nov. 12, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AM-Pharma, Astrazeneca, Cardior, CG, CNS, Denovo, Effector, Epygenix, GSK, Inhibrx, Kahr, Medicago, Maat, Moderna, Organicell, Selva, Tissuetech, Wize.
Read More
Regulatory front

Federal Circuit reverses lower court in Bard/Angiodynamics patent suit

Nov. 11, 2020
By Mark McCarty
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: FDA warning letter to company promoting test kits.
Read More
Previous 1 2 … 335 336 337 338 339 340 341 342 343 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing